<DOC>
	<DOCNO>NCT00913055</DOCNO>
	<brief_summary>To evaluate pharmacokinetic ( PK ) pharmacodynamic ( PD ) response hydrate non-hydrated 84 mg octreotide implant patient acromegaly first 6 week treatment .</brief_summary>
	<brief_title>Open Label Study Octreotide Implant Patients With Acromegaly</brief_title>
	<detailed_description>An open-label , randomize , multi-center , parallel-group , Phase I/II study conduct 30 male female patient acromegaly . Eligible patient receive 1 implant , either hydrate non-hydrated , within 7 day Screening Visit . The octreotide implant insert subcutaneously inner aspect non-dominant arm local anesthesia . Blood sample determination insulin-like growth factor 1 ( IGF-1 ) , growth hormone ( GH ) , octreotide serum concentration collect predetermined timepoints within first 6 week implantation .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Dimenhydrinate</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Male female patient acromegaly Must least 18 year old Confirmed diagnosis growth hormone secrete tumor Must either full partial responder octreotide demonstrate historical laboratory value Women pregnant , lactate childbearing potential practicing medically acceptable method birth control Patients liver disease Patients symptomatic cholelithiasis Patients receive radiotherapy pituitary tumor time Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>S-LAR</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Implant</keyword>
</DOC>